Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the secon

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024,

Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product

AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline results

Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,

Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growthAuvelity® 3Q 2024 net product sales of $80.4 million,